Annovis Bio Inc

Annovis Bio Inc

ANVS - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$31.04M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Annovis Bio IncAnnovis Bio Inc-0.5-933%--
$0.95

Current Fair Value

14.9% upside

Undervalued by 14.9% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$31.04 Million
Enterprise Value$-18,697,901,963.00
Earnings per Share$-1.4
Beta1.35
Outstanding Shares37,518,778

Return

Return on Equity933.10%ROE
Return on Assets-180.15%
Return on Invested Capital-46.38%

Valuation & Multiples

P/E Ratio-0.47P/E Ratio
PEG0PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.01Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT2.57
Enterprise Value to Net Income0
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 18, 2026
EPS Estimate
$-0.45
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
November 11, 2026
EPS Estimate
$-0.30
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.0000▼ 31.69%
Total Calls10,000▼ 98.92%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %0.09%▼ 38.88%
Total Invested$43,754▼ 99.78%
Investors Holding6▼ 63.00%

About Annovis Bio Inc

CEO: Maria Maccecchini

Annovis Bio Insider Information FAQ

Stockcircle tracks 4 top investors with a current 13F position in Annovis Bio. Holdings come from the latest quarterly 13F filings filed with the SEC.

In the latest 13F quarter on Stockcircle, 3 top investors increased or opened positions among tracked top investors. Changes are based on reported share counts in their quarterly filings, not day-to-day trading.

Stockcircle shows 1 open-market insider purchase for Annovis Bio in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.